| Identification of nephrotoxic compounds with embryonic stem-cell-derived human renal proximal tubular-like cells Y Li, K Kandasamy, JKC Chuah, YN Lam, WS Toh, ZY Oo, D Zink Molecular pharmaceutics 11 (7), 1982-1990, 2014 | 78 | 2014 |
| The performance of primary human renal cells in hollow fiber bioreactors for bioartificial kidneys ZY Oo, R Deng, M Hu, M Ni, K Kandasamy, MS Bin Ibrahim, JY Ying, ... Biomaterials 32 (34), 8806-8815, 2011 | 77 | 2011 |
| An in vitro method for the prediction of renal proximal tubular toxicity in humans Y Li, ZY Oo, SY Chang, P Huang, KG Eng, JL Zeng, AJ Kaestli, B Gopalan, ... Toxicology Research 2 (5), 352-365, 2013 | 70 | 2013 |
| Aurora A is critical for survival in HPV-transformed cervical cancer B Gabrielli, F Bokhari, MV Ranall, ZY Oo, AJ Stevenson, W Wang, ... Molecular cancer therapeutics 14 (12), 2753-2761, 2015 | 39 | 2015 |
| A novel design of bioartificial kidneys with improved cell performance and haemocompatibility ZY Oo, K Kandasamy, F Tasnim, D Zink Journal of cellular and molecular medicine 17 (4), 497-507, 2013 | 29 | 2013 |
| Broad-spectrum solvent-free layered black phosphorus as a rapid action antimicrobial ZL Shaw, S Kuriakose, S Cheeseman, ELH Mayes, A Murali, ZY Oo, ... ACS Applied Materials & Interfaces 13 (15), 17340-17352, 2021 | 25 | 2021 |
| Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine ZY Oo, M Proctor, AJ Stevenson, D Nazareth, M Fernando, SM Daignault, ... Molecular oncology 13 (7), 1503-1518, 2019 | 22 | 2019 |
| Label-free imaging of fibroblast membrane interfaces and protein signatures with vibrational infrared photothermal and phase signals PD Samolis, D Langley, BM O’Reilly, Z Oo, G Hilzenrat, S Erramilli, ... Biomedical optics express 12 (1), 303-319, 2021 | 20 | 2021 |
| Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo ZY Oo, AJ Stevenson, M Proctor, SM Daignault, S Walpole, C Lanagan, ... Clinical Cancer Research 24 (12), 2901-2912, 2018 | 16 | 2018 |
| Cell cycle checkpoint and DNA damage response defects as anticancer targets: From molecular mechanisms to therapeutic opportunities L Spoerri, ZY Oo, JE Larsen, NK Haass, B Gabrielli, S Pavey Stress response pathways in cancer: From molecular targets to novel …, 2015 | 16 | 2015 |
| Extending In-Plane Impedance Measurements from 2D to 3D Cultures: Design Considerations SE De Leon, L Cleuren, ZY Oo, PR Stoddart, SL McArthur Bioengineering 8 (1), 11, 2021 | 2 | 2021 |
| An in vitro method for the prediction of renal proximal tubular toxicity in humans. Toxicol Res 2 (5): 352–365 Y Li, ZY Oo, SY Chang, P Huang, KG Eng, JL Zeng, D Zink | 2 | 2013 |
| Imaging membrane interfaces and secondary protein conformation in cell cultures with vibrational infrared photothermal and phase signal (VIPPS) microscopy PD Samolis, D Langley, BM O'Reilly, Z Oo, G Hilzenrat, S Erramilli, ... Ultrafast Nonlinear Imaging and Spectroscopy IX 11825, 118250J, 2021 | | 2021 |
| 3D in-vitroneuronal cultures for studying cell-material interactions A Sabu, ZY Oo, B Farrugia, S McArthur Australian Biomedical Engineering Conference 2021 (ABEC 2021): Virtual …, 2021 | | 2021 |
| Extending In-Plane Impedance Measurements from 2D to 3D Cultures: Design Considerations. Bioengineering 2021, 8, 11 SE De Leon, L Cleuren, ZY Oo, PR Stoddart, SL McArthur s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in …, 2021 | | 2021 |
| Subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors for optimal tumor control and immune responses in vitro and in vivo ZY Oo, M Proctor, A Stevenson, D Nazareth, J Larsen, N Haass, ... Cancer Research 79 (13_Supplement), 1236-1236, 2019 | | 2019 |
| Increasing replication stress by reducing nucleoside levels sensitizes melanomas and non-small cell lung cancers to CHK1 inhibitor in vitro and in vivo ZY Oo, M Proctor, A Stevenson, J Larsen, BG Gabrielli MOLECULAR CANCER THERAPEUTICS 17 (1), 2018 | | 2018 |
| Abstract A069: Increasing replication stress by reducing nucleoside levels sensitizes melanomas and non-small cell lung cancers to CHK1 inhibitor in vitro and in vivo ZY Oo, M Proctor, A Stevenson, J Larsen, BG Gabrielli Molecular Cancer Therapeutics 17 (1_Supplement), A069-A069, 2018 | | 2018 |
| Mechanisms and markers of CHK1 inhibitors sensitivity in melanoma ZY Oo | | 2017 |
| Defect in S phase cell cycle checkpoint renders tumours vulnerable to CHK1 inhibitor single-agent treatment in vitro and in vivo ZY Oo, A Stevenson, C Lanagan, L Spoerri, J Larsen, B Gabrielli MOLECULAR CANCER RESEARCH 15, 2017 | | 2017 |
